Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5204660 | 0.94 | MAPK14 (0.70) | MAPK14CYP2C9CYP2C19MEN1KMT2A | |
| SCHEMBL3492151 | 0.93 | MAPK14 (0.68) | MAPK14CYP2C9CYP2C19MEN1KMT2A | |
| SCHEMBL13954889 | 0.92 | MAPK14 (0.68) | MAPK14CYP2C9CYP2C19MEN1KMT2A | |
| SCHEMBL5207614 | 0.92 | MAPK14 (0.68) | MAPK14CYP2C9CYP2C19MEN1KMT2A | |
| SCHEMBL14561246 | 0.92 | MAPK14 (0.68) | MAPK14CYP2C9CYP2C19MEN1KMT2A | |
| SCHEMBL20883163 | 0.91 | MAPK14 (0.83) | MAPK14CYP2C9CYP2C19MEN1KMT2A | |
| SCHEMBL5201697 | 0.89 | MAPK14 (0.64) | MAPK14CYP2C9CYP2C19MEN1KMT2A | |
| SCHEMBL14440277 | 0.86 | MAPK14 (0.70) | MAPK14CYP2C9CYP2C19MEN1KMT2A | |
| SCHEMBL5204474 | 0.86 | MAPK14 (0.83) | MAPK14CYP2C9CYP2C19MEN1KMT2A | |
| SCHEMBL5201431 | 0.85 | MAPK14 (0.59) | MAPK14CYP2C9CYP2C19MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190105311-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2019-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105311-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 196/4885CYP2C9 4695/4885CYP2C19 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.